Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
EpilepsyTonic-clonicAn open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.
A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated...
EpilepsyTo assess the efficacy and safety of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
EpilepsiesPartial2 moreThe primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Seizure DisorderPartialTo evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.
Pediatric Epilepsy Study in Subjects 1-24 Months
EpilepsyThis study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.
Early Surgical Intervention to Treat Epilepsy
EpilepsyEpilepsy2 moreThe purpose of this trial is to compare the effectiveness of early surgical intervention for mesial temporal lobe epilepsy to continued treatment with antiepileptic drugs.
Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized...
Generalized EpilepsyEpilepsy is one of the most common and frequently encountered neurological conditions that impose a huge burden on the healthcare systems. Despite the abundance of antiepileptic drugs (AEDs) available, 30% of people continue to have seizures even after long-term therapy of 6-8 years. This group of people requires a more aggressive treatment since monotherapy, the first choice scheme, is not sufficient to control seizure and its complications, multiple drug therapy or polytherapy often results in the culmination of unwanted effects. The need for an add-on AEDs with a good safety profile is of utmost importance.The beneficial effects of melatonin on sleep, its wide safety window, and its ability to cross the blood-brain barrier have the potential to improve the quality of life in seizure patients. Various animal studies have suggested that melatonin receptors are the potential targets for anticonvulsant drug development. In animal studies, melatonin was found to suppress generalized seizure and seizure susceptibility and it also has neuroprotection and synapse modulating properties. Some clinical trials mostly on paediatric population also found that melatonin can improve the clinical outcome in epilepsy. Therefore, we have planned to conduct a randomized, add-on placebo-controlled clinical trial on the effect of melatonin on seizure outcome, neuronal damage and quality of life in adult patients with generalized seizure.
A Study of Intravenous Perampanel in Japanese Participants With Epilepsy
EpilepsySeizuresThe purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day [mg/day]) as an adjunctive therapy in participants with epilepsy with partial onset seizures (POS) (including secondarily generalized seizures) or primary generalized tonic-clonic (PGTC) seizures.
Memantine for Epileptic Encephalopathy
Epileptic EncephalopathyChildhood-OnsetThis study will evaluate the potential benefit of memantine hydrochloride as treatment for children with epileptic encephalopathy using a double-blind placebo-controlled cross-over design.
Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With...
EpilepsyThe objectives of this study were to assess the tolerability and safety of E2007 in patients with refractory partial or generalised seizures and to assess the pharmacokinetics of E2007 in epileptic patients receiving at least one concomitant anti-epileptic drug.